STAA

Staar Surgical Co Health Care Ophthalmic Goods Russell 3000

$24.54Close $1.2BMarket cap $16.10 – $33.3452-week range Nov 4, 2026Next report · after the close

Highlights

Cautions

Not in an uptrend 3 of 8 trend conditions
Lagging the market RS 49 · weaker than 51% of stocks over 12 months
Far from its high 26% below its 52-week high
Results soon Nov 4, 2026, in 3 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Jan 2, 2026 · filed Aug 12, 2026

Off 12-month high 26%

1wk 8.5% price change

1mo 8.5% price change

12-month return 8% market up 11% · its own down 19%

F-score 2 / 9 Weak

Altman Z 6.81 Low risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B 3.5× price / book

Earnings yield 8.7% EBIT / enterprise value

Cheaper than 24% of the market · expensive

Revenue growth 24% year on year

EPS growth — latest quarter

Sales growth 111% latest quarter · -9 pts

ROE 22% return on equity

Free cash margin 17% -$40.0M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Piotroski tests

not yet profitable on its assets
operating cash flow is negative
profitability slipped from last year
short-term liquidity weakened
issued more shares
gross margin narrowed
assets working less efficiently
profits backed by cash
reduced long-term debt

Trade setup

ATR% 3.9% $0.96 a day · 2×ATR $22.61

RS 49 / 99 vs the universe

Trend 3 / 8 trend template

Relative volume 0.6× vs 50-day average

Up/down volume 0.91 50 sessions

Implied move — no option chain · report Nov 4, 2026

Trend template · 3 of 8

Price above the 150 and 200-day averages: fails
150-day average above the 200-day: passes
200-day average rising for a month: fails
50-day average above the 150 and 200-day: fails
Price above the 50-day average: passes
At least 30% above the 52-week low: passes
Within 25% of the 52-week high: fails
RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Revenue shrinking Revenue fell 23.7% over the year, from $313.9M to $239.4M.

Last reported Aug 12, 2026

Results reaction Aug 12, 2026+1% vs market2 sessions after results

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $239.4M -24% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$80.4M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$40.0M

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 76%
Net -34%
Free cash -17%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 49.40m +6.3% since FY2020

	FY2020Jan 1, 2021	FY2021Dec 31, 2021	FY2022Dec 30, 2022	FY2023Dec 31, 2023	FY2024Dec 27, 2024	FY2025Jan 2, 2026
Revenue	$22.1M	$230.5M	$239.4M	$322.4M	$313.9M	$239.4M
Gross margin	537%	78%	93%	78%	76%	76%
Operating income	$6.8M	$33.3M	$43.8M	$28.1M	-$12.6M	-$91.7M
Net income	$5.9M	$27.5M	$39.7M	$21.3M	-$20.2M	-$80.4M
Net margin	27%	12%	17%	7%	-6%	-34%
Earnings per share	$0.12	$0.56	$0.80	$0.43	-$0.41	-$1.62
Free cash flow	$12.5M	$30.3M	$17.6M	-$3.6M	-$7.7M	-$40.0M
Free cash margin	57%	13%	7%	-1%	-2%	-17%
Cash	$152.5M	$199.7M	$86.5M	$183.0M	$144.2M	$153.2M
Shareholders' equity	$197.2M	$261.6M	$336.1M	$386.0M	$397.3M	$344.2M
Shares outstanding	46.49m	47.72m	48.21m	48.84m	49.29m	49.40m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 12, 2026	Quarterly ↗	Jul 3, 2026	40d
May 13, 2026	Quarterly ↗	Apr 3, 2026	40d
Mar 3, 2026	Annual ↗	Jan 2, 2026	60d
Nov 5, 2025	Quarterly ↗	Sep 26, 2025	40d
Aug 6, 2025	Quarterly ↗	Jun 27, 2025	40d
May 7, 2025	Quarterly ↗	Mar 28, 2025	40d
Feb 21, 2025	Annual ↗	Dec 27, 2024	56d
Oct 30, 2024	Quarterly ↗	Sep 27, 2024	33d
Aug 7, 2024	Quarterly ↗	Jun 28, 2024	40d
May 7, 2024	Quarterly ↗	Mar 29, 2024	39d
Feb 27, 2024	Annual ↗	Dec 29, 2023	60d
Nov 6, 2023	Quarterly ↗	Sep 29, 2023	38d

Current reports

Filed	Disclosed
Sep 10, 2026	Director or officer change · Regulation FD ↗
Aug 12, 2026	Results · Regulation FD ↗
Aug 6, 2026	Director or officer change · Regulation FD ↗
Jun 22, 2026	Director or officer change · Shareholder vote ↗
Jun 9, 2026	Director or officer change ↗
May 13, 2026	Results · Regulation FD ↗
Apr 8, 2026	Regulation FD ↗
Mar 3, 2026	Results · Regulation FD ↗
Feb 5, 2026	Director or officer change ↗
Feb 2, 2026	Director or officer change · Regulation FD ↗
Jan 16, 2026	Director or officer change ↗
Jan 15, 2026	Material agreement · Listing notice · Director or officer change · Other events ↗